Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

BCX9930 til behandling af C3G, IgAN og PMN (RENEW) (RENEW)

27. oktober 2026 opdateret af: BioCryst Pharmaceuticals

En åben-label, sikkerhed, tolerabilitet og proof-of-concept undersøgelse af oral BCX9930-terapi hos forsøgspersoner med C3G, IgAN eller PMN

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

2

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Oxford, Det Forenede Kongerige
        • Investigative Site
      • Poitiers, Frankrig
        • Investigative Site
      • Toulouse, Frankrig
        • Investigative Site
      • Bari, Italien
        • Investigative Site
      • Bergamo, Italien
        • Investigative Site
      • Brescia, Italien
        • Investigative Site
      • Turin, Italien
        • Investigative Site
      • Barcelona, Spanien
        • Investigative Site #1
      • Barcelona, Spanien
        • Investigative Site #2
      • Madrid, Spanien
        • Investigative Site #1
      • Madrid, Spanien
        • Investigative Site #2

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Body weight ≥ 40 kilograms (kg)
  • Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review
  • An estimated glomerular filtration rate (eGFR) ≥ 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or ≥ 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation)
  • Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit
  • Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series

Exclusion Criteria:

  • Known congenital deficiency of C1s, C1r, C1q, C2, or C4
  • History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
  • Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
  • History of malignancy within 5 years prior to the screening visit
  • Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
  • Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
  • Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: C3G cohort

Approximately 14 eligible participants with C3G will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Eksperimentel: IgAN cohort

Approximately 14 eligible participants with IgAN will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Eksperimentel: PMN cohort

Approximately 14 eligible participants with PMN will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent Change From Baseline in 24-hour uPCR at Week 12
Tidsramme: Baseline, Week 12

Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease.

Baseline, Week 12
Percent Change From Baseline in 24-hour uPCR at Week 24
Tidsramme: Baseline, Week 24

Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease.

Baseline, Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Procent ændring fra baseline i 24-timers urinproteinudskillelse
Tidsramme: Baseline, uge ​​12, 24,
Baseline, uge ​​12, 24,
Change From Baseline in Estimated Glomerular Filtration Rate
Tidsramme: Baseline, Weeks 12, 24

eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants ≥ 18 years old and by the bedside Schwartz formula for participants ≤ 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2).

Baseline, Weeks 12, 24
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Tidsramme: From first dose up to safety follow-up period (Week 28)

An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Discontinued Due to a TEAE
Tidsramme: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE)
Tidsramme: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:

  • Death
  • Is life-threatening (participant was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe)
  • Requires participant hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity (ie, there was a substantial disruption of a person's ability to carry out normal life functions)
  • Is a congenital anomaly/birth defect
From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE
Tidsramme: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study.

TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5.

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL

Grade 4: Life-threatening consequences; urgent intervention indicated

Grade 5: Death

Participants with Grades 3 or 4 AEs were reported

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality
Tidsramme: From first dose up to safety follow-up period (Week 28)

Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

CTCAE Grades for laboratory abnormalities include:

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.

Grade 4: Life-threatening consequences; urgent intervention indicated.

Grade 5: Death

Participants with Grades 3 or 4 laboratory abnormality were reported.

From first dose up to safety follow-up period (Week 28)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Carla M Nester, MD, MSA, FASN, University of Iowa Stead Family Children's Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

18. februar 2022

Primær færdiggørelse (Faktiske)

23. september 2022

Studieafslutning (Faktiske)

23. september 2022

Datoer for studieregistrering

Først indsendt

26. november 2021

Først indsendt, der opfyldte QC-kriterier

16. december 2021

Først opslået (Faktiske)

17. december 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • BCX9930-211
  • 2020-005855-19 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .